Halozyme Therapeutics, Inc. $HALO Shares Bought by Principal Financial Group Inc.

Principal Financial Group Inc. grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 264,490 shares of the biopharmaceutical company’s stock after acquiring an additional 12,438 shares during the period. Principal Financial Group Inc.’s holdings in Halozyme Therapeutics were worth $17,094,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Measured Wealth Private Client Group LLC increased its holdings in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares in the last quarter. Larson Financial Group LLC lifted its stake in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 343 shares during the period. Harbour Investments Inc. boosted its holdings in Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 372 shares in the last quarter. Clearstead Advisors LLC boosted its holdings in Halozyme Therapeutics by 64.8% during the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 331 shares in the last quarter. Finally, Wexford Capital LP acquired a new position in Halozyme Therapeutics during the third quarter worth about $70,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares of the company’s stock, valued at $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the sale, the director owned 42,044 shares in the company, valued at $3,225,195.24. This represents a 3.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 74,102 shares of company stock valued at $5,205,798. Corporate insiders own 2.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on HALO shares. HC Wainwright reaffirmed a “buy” rating and issued a $95.00 target price on shares of Halozyme Therapeutics in a report on Tuesday. UBS Group restated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Finally, Morgan Stanley decreased their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Stock Down 1.0%

HALO stock opened at $77.82 on Thursday. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The company’s 50 day simple moving average is $72.55 and its 200-day simple moving average is $70.43. Halozyme Therapeutics, Inc. has a 12 month low of $57.33 and a 12 month high of $82.26. The firm has a market capitalization of $9.23 billion, a PE ratio of 27.99, a P/E/G ratio of 0.33 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. During the same period in the previous year, the firm posted $1.11 EPS. The company’s quarterly revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities analysts expect that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.